Sells WAKIX, a narcolepsy medicine, through specialty distributors and develops treatments for sleep disorders, rare epilepsy and other neurological diseases.
10-K for FY2025, filed Feb 24, 2026In July 2017, we entered into a License Agreement (as amended, the “2017 LCA”) with Bioprojet Société Civile de Recherche (“Bioprojet”)…View ↗
In April 2024, we expanded into orexin science through a sublicense agreement with Bioprojet for an orexin 2 receptor agonist (“BP1.15205”)…View ↗
We sell WAKIX to a limited number of specialty distributors, that, in turn, distribute WAKIX to patients. We do not currently own or…View ↗
Harmony sells WAKIX to specialty distributors; each product sale counts when the medicine is delivered to the buyer.
10-K for FY2025, filed Feb 24, 2026
$868.5M
10-K for FY2025, filed Feb 24, 2026
$868.5M ↗
Harmony sells WAKIX to a limited number of specialty distributors, which then distribute it to patients.
10-K for FY2025, filed Feb 24, 2026We sell WAKIX to a limited number of specialty distributors, that, in turn, distribute WAKIX to patients. We do not currently own or…View ↗
10-K for FY2025, filed Feb 24, 2026
For the year ended December 31, 2025, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 38% of gross…View ↗
Yes. It kept 18 cents of every revenue dollar as net income in FY2025 and turned 40 cents into free cash flow.
8-K, filed Aug 4, 2026
WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950…View ↗
8-K, filed Jul 16, 2026
On July 16, 2026, the Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s…View ↗
8-K, filed May 7, 2026
Reiterated 2026 WAKIX Net Revenue Guidance of $1.0 Billion – $1.04 BillionView ↗
8-K, filed Apr 14, 2026
On April 14, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) announced that Sandip Kapadia, the Company’s Chief Financial Officer…View ↗
Growing. Revenue grew 2.8x in 4 years, from $305.4M in FY2021 to $868.5M in FY2025, about 30% a year.
Broader development portfolio
Earlier reports centered on pitolisant, with a preclinical asset under study for metabolic effects; the latest report also describes an orexin-based candidate, rare-epilepsy candidates and cell-replacement research.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 24, 2026
Competes with Jazz Pharmaceuticals, Axsome, Avadel Pharmaceuticals, Alkermes, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Aardvark Therapeutics, Rhythm Pharmaceuticals, Palobiofarma, Avidity Biosciences, Vertex Pharmaceuticals, Entrada Therapeutic, PepGen, UCB, Biocodex, Eisai, Janssen, GlaxoSmithKline, Assertio Holdings, and Stoke Therapeutics
10-K for FY2025, filed Feb 24, 2026WAKIX competes with currently FDA-approved products for the treatment of EDS and/or cataplexy in adults and pediatric patients six years…View ↗
Loading...